Phase 2 study of CHOP‑R‑14 followed by 90Y‑ibritumomab tiuxetan in patients with previously untreated diffuse large B‑cell lymphoma

  • Authors:
    • Reem Karmali
    • Melissa L. Larson
    • Jamile M. Shammo
    • Stephanie A. Gregory
    • Teresa O'brien
    • Parameswaran Venugopal
  • View Affiliations

  • Published online on: Friday, February 17, 2017
  • DOI: 10.3892/mco.2017.1169
0

Abstract

The aim of this open‑label, single‑center, phase 2 study was to assess the efficacy and safety of dose‑dense CHOP‑R‑14 followed by 90Y‑ibritumomab radioimmunotherapy (RIT) in patients with previously untreated diffuse large B‑cell lymphoma (DLBCL). A total of 20 patients, the majority presenting with high‑risk characteristics, were enrolled to receive dose‑dense cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab every 14 days (CHOP‑R‑14), followed by 90Y‑ibritumomab tiuxetan consolidation. Sixteen patients completed RIT consolidation (rituximab 250 mg/m2 on day 1 and day 7, 8, or 9, followed by a single injection of 90Y‑ibritumomab). Complete response (CR) rates of 75 and 95% were observed after treatment with CHOP‑R‑14 and RIT, respectively; 4 of the 5 patients who achieved a partial response after CHOP‑R‑14 converted to CR following treatment with RIT. With a median follow‑up of 89.7 months, the progression‑free and overall survival rates for the cohort were 75 and 85%, respectively. Hematological adverse events were common following CHOP‑R‑14 and RIT, but they were manageable with treatment interruption. Therefore, this regimen achieved promising survival outcomes in high‑risk DLBCL on long term follow‑up, with manageable toxicity.

Related Articles

Journal Cover

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Karmali, R., Larson, M.L., Shammo, J.M., Gregory, S.A., O'brien, T., & Venugopal, P. (1899). Phase 2 study of CHOP‑R‑14 followed by 90Y‑ibritumomab tiuxetan in patients with previously untreated diffuse large B‑cell lymphoma. Molecular and Clinical Oncology, 0, 0-0. http://dx.doi.org/10.3892/mco.2017.1169
MLA
Karmali, R., Larson, M. L., Shammo, J. M., Gregory, S. A., O'brien, T., Venugopal, P."Phase 2 study of CHOP‑R‑14 followed by 90Y‑ibritumomab tiuxetan in patients with previously untreated diffuse large B‑cell lymphoma". Molecular and Clinical Oncology 0.0 (1899): 0-0.
Chicago
Karmali, R., Larson, M. L., Shammo, J. M., Gregory, S. A., O'brien, T., Venugopal, P."Phase 2 study of CHOP‑R‑14 followed by 90Y‑ibritumomab tiuxetan in patients with previously untreated diffuse large B‑cell lymphoma". Molecular and Clinical Oncology 0, no. 0 (1899): 0-0. http://dx.doi.org/10.3892/mco.2017.1169